Quantification of Filovirus Glycoprotein-Specific Antibodies

Wakako Furuyama; Hiroko Miyamoto; Reiko Yoshida; Ayato Takada

doi:10.1007/978-1-4939-7116-9_25

Quantification of Filovirus Glycoprotein-Specific Antibodies

Methods Mol Biol. 2017:1628:309-320. doi: 10.1007/978-1-4939-7116-9_25.

Authors

Wakako Furuyama¹, Hiroko Miyamoto¹, Reiko Yoshida¹, Ayato Takada²

Affiliations

¹ Division of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
² Division of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan. atakada@czc.hokudai.ac.jp.

PMID: 28573631
DOI: 10.1007/978-1-4939-7116-9_25

Abstract

Serological methods such as the enzyme-linked immunosorbent assay (ELISA) and virus neutralization test are fundamental tools used in diagnosis, seroepidemiological studies of filovirus transmission/prevalence, and the evaluation of vaccine immunogenicity and potential therapeutic antibodies. Filoviruses have a single transmembrane glycoprotein (GP), which is the only known target of neutralizing antibodies. Here we describe serological methods to quantify filovirus GP-specific antibodies.

Keywords: ADE; Antibody; Antibody-dependent enhancement; ELISA; Ebolavirus; Filovirus; Glycoprotein; Marburgvirus; Neutralization.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antibodies, Neutralizing / immunology
Antibodies, Neutralizing / isolation & purification*
Antibodies, Viral / immunology
Antibodies, Viral / isolation & purification
Ebolavirus / immunology
Ebolavirus / pathogenicity
Enzyme-Linked Immunosorbent Assay / methods*
Glycoproteins / immunology
Glycoproteins / isolation & purification
Hemorrhagic Fever, Ebola / immunology*
Hemorrhagic Fever, Ebola / prevention & control
Hemorrhagic Fever, Ebola / virology
Humans
Viral Vaccines / immunology*
Viral Vaccines / pharmacology

Substances

Antibodies, Neutralizing
Antibodies, Viral
Glycoproteins
Viral Vaccines